Suppr超能文献

韩国嗜麦芽寡养单胞菌分离株的抗菌药敏性及抗菌药物组合对分离株的活性。

Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.

机构信息

Department of Laboratory Medicine and Research Institute of Antimicrobial Resistance, Yonsei University College of Medicine, Seoul, Korea.

出版信息

J Korean Med Sci. 2013 Jan;28(1):62-6. doi: 10.3346/jkms.2013.28.1.62. Epub 2013 Jan 8.

Abstract

The aim of this study was to determine antimicrobial susceptibility of recent clinical Stenotrophomonas maltophilia isolates from Korea, and to compare the activity levels of several combinations of antimicrobials. A total of 206 non-duplicate clinical isolates of S. maltophilia was collected in 2010 from 11 university hospitals. Antimicrobial susceptibility testing was performed using the Clinical Laboratory Standards Institute agar dilution method. In vitro activity of antimicrobial combinations was tested using the checkerboard method. The susceptibility rates to trimethoprim-sulfamethoxazole and minocycline were 96% and 99%, respectively. The susceptibility rate to levofloxacin was 64%. All of four antimicrobial combinations showed synergy against many S. maltophilia isolates. A combination of trimethoprim-sulfamethoxazole plus ticarcillin-clavulanate was most synergistic among the combinations. None of the combinations showed antagonistic activity. Therefore, some of the combinations may be more useful than individual drugs in the treatment of S. maltophilia infection. Further clinical studies are warranted to validate our in vitro test results.

摘要

本研究旨在确定韩国近期临床嗜麦芽寡养单胞菌分离株的抗菌药物敏感性,并比较几种抗菌药物组合的活性水平。2010 年,从 11 所大学医院共收集了 206 株非重复的嗜麦芽寡养单胞菌临床分离株。采用临床和实验室标准协会琼脂稀释法进行抗菌药物敏感性试验。采用棋盘微量稀释法检测抗菌药物组合的体外活性。对复方磺胺甲噁唑和米诺环素的敏感性率分别为 96%和 99%,左氧氟沙星的敏感性率为 64%。四种抗菌药物组合均对许多嗜麦芽寡养单胞菌分离株表现出协同作用。复方磺胺甲噁唑加替卡西林克拉维酸的组合最具协同作用。组合中没有一种显示拮抗作用。因此,一些组合在治疗嗜麦芽寡养单胞菌感染方面可能比单独使用药物更有效。需要进一步的临床研究来验证我们的体外试验结果。

相似文献

4
Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations.
J Chemother. 2014 Oct;26(5):282-6. doi: 10.1179/1973947814Y.0000000168. Epub 2014 Mar 4.
5
In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates.
Turk J Med Sci. 2019 Apr 18;49(2):683-686. doi: 10.3906/sag-1808-55.
8
Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
Microb Drug Resist. 2017 Mar;23(2):163-168. doi: 10.1089/mdr.2015.0228. Epub 2016 Jun 13.
9
Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing.
J Infect Chemother. 2010 Oct;16(5):322-8. doi: 10.1007/s10156-010-0068-2. Epub 2010 May 7.
10
A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
J Microbiol Immunol Infect. 2012 Apr;45(2):120-6. doi: 10.1016/j.jmii.2011.09.028. Epub 2011 Dec 11.

引用本文的文献

1
Investigation and Management of a Small Outbreak of Septic Knee Arthritis Following Knee Arthroscopy by .
J Med Cases. 2025 Jul 8;16(7):239-247. doi: 10.14740/jmc5138. eCollection 2025 Jul.
2
Osteomyelitis due to Stenotrophomonas maltophilia treated with trimethoprim-sulfamethoxazole monotherapy.
IDCases. 2023 May 12;32:e01798. doi: 10.1016/j.idcr.2023.e01798. eCollection 2023.
3
Global prevalence and antibiotic resistance in clinical isolates of : a systematic review and meta-analysis.
Front Med (Lausanne). 2023 May 5;10:1163439. doi: 10.3389/fmed.2023.1163439. eCollection 2023.
4
Risk Factors for Mortality in Hospitalized Patients with Bacteremia.
Infect Drug Resist. 2022 Jul 21;15:3881-3886. doi: 10.2147/IDR.S371129. eCollection 2022.
6
as a rare cause of meningitis and ventriculoperitoneal shunt infection.
Access Microbiol. 2021 Oct 7;3(10):000266. doi: 10.1099/acmi.0.000266. eCollection 2021.
7
A prospective study of microbiological characterization and clinical facets of infections.
Iran J Microbiol. 2020 Aug;12(4):313-318. doi: 10.18502/ijm.v12i4.3934.
8
Characterization of Novel Broad-Host-Range Bacteriophage DLP3 Specific to as a Potential Therapeutic Agent.
Front Microbiol. 2020 Jun 24;11:1358. doi: 10.3389/fmicb.2020.01358. eCollection 2020.

本文引用的文献

2
Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.
Clin Microbiol Rev. 2012 Jan;25(1):2-41. doi: 10.1128/CMR.00019-11.
4
A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
J Microbiol Immunol Infect. 2012 Apr;45(2):120-6. doi: 10.1016/j.jmii.2011.09.028. Epub 2011 Dec 11.
5
Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment.
Expert Rev Anti Infect Ther. 2011 Apr;9(4):471-88. doi: 10.1586/eri.11.24.
6
Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing.
J Infect Chemother. 2010 Oct;16(5):322-8. doi: 10.1007/s10156-010-0068-2. Epub 2010 May 7.
9
Stenotrophomonas maltophilia: an emerging opportunist human pathogen.
Lancet Infect Dis. 2009 May;9(5):312-23. doi: 10.1016/S1473-3099(09)70083-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验